IV/IT hUC-MSCs Infusion in RRMS and NMO: A 10-Year Follow-Up Study
Conclusions: These data suggest that combined intravenous and intrathecal low-dose hUC-MSCs transplantation is safe and feasible in RRMS and NMO patients in the long term. The conclusion requires confirmation by future clinical trials in a larger cohort.
Source: Frontiers in Neurology - Category: Neurology Source Type: research
More News: Autoimmune Disease | Brain | Clinical Trials | Disability | Multiple Sclerosis | Neurology | Stem Cell Therapy | Stem Cells | Study | Transplants